U.S. equities reached all-time highs on Thursday as President Trump announced a 10-day ceasefire between Israeli and Lebanese leaders. The S&P 500 advanced to 7,038.57 (+0.2%), while the Nasdaq 100 rallied 0.6% to 26,359 on its 12th straight session of gains. Oil prices surged on Iran's Hormuz toll legislation, with WTI crude jumping 2.5% to $93.58. Energy and technology sectors led gains, though healthcare stocks declined following weak guidance from Abbott Laboratories.

Summit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.

The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated non-small cell lung cancer patients. The drug will undergo complete review with a PDUFA goal action date of November 14, 2026. Phase 3 trial data showed ivonescimab demonstrated improved overall survival compared to chemotherapy alone, and the company is expanding its clinical development program with additional Phase 3 studies.

Ten large-cap stocks experienced significant declines during the week of January 12-16, 2026. Regencell Bioscience led losses with a 42.08% drop, while Trip.com fell 20.19% following a Chinese anti-monopoly investigation. Other major decliners included Atlassian (19.82%), Figma (19.41%), HubSpot (16.56%), and Intuit (14.38%), with analyst downgrades cited for several stocks.

Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.

Summit Therapeutics, a healthcare company with a $14 billion market cap, is banking on its promising cancer drug ivonescimab, which showed potential superiority to Keytruda in clinical trials. However, the stock remains risky due to ongoing global trials and uncertain FDA approval.

Wall Street analysts highlight three potential comeback stocks across different sectors: The Trade Desk, Summit Therapeutics, and Sprouts Farmers Market, each facing challenges but showing promising signs of recovery.

Summit Therapeutics reported positive Phase 3 trial results for ivonescimab in lung cancer treatment, showing a 40% reduced risk of progression or death compared to competitor therapy, and plans to submit a Biologics License Application in Q4 2025.

Pomerantz LLP is investigating potential securities fraud by Summit Therapeutics after its clinical trial for ivonescimab showed mixed results, causing significant stock price drops in May and September 2025.

Summit Therapeutics experienced significant stock price drops after announcing clinical trial results for ivonescimab, which failed to meet overall survival metrics. The Portnoy Law Firm is investigating potential securities fraud related to these disclosures.

Summit Therapeutics reported updated Phase 3 trial results for ivonescimab, a lung cancer drug, showing improved overall survival in Western patients but with regional performance variations that impacted stock performance.

The article explores two promising biotech companies, Viking Therapeutics and Recursion Pharmaceuticals, highlighting their innovative approaches in weight loss treatments and AI-driven drug development, respectively.